急性冠脉综合征患者血清高敏C反应蛋白和组织蛋白酶S水平变化与临床意义

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (9): 1036-1039.

急性冠脉综合征患者血清高敏C反应蛋白和组织蛋白酶S水平变化与临床意义

周碧蓉, 陈越峰, 周娜, 杨景

安徽医科大学第一附属医院心内科,合肥 230022,安徽

收稿日期:2013-07-06 修回日期:2013-08-08 发布日期:2013-09-07
作者简介:周碧蓉,女,博士,副主任医师,副教授,硕士生导师,研究方向:动脉粥样硬化基础与临床。Tel: 0551-62922062 E-mail: zhoubirong1@hotmail.com
基金资助:
安徽高校省级自然科学研究重点项目资助(KJ2011A158)

Changes of hs-CRP, CatS level in acute coronary syndrome patients serum and clinical significance

ZHOU Bi-rong, CHEN Yue-feng, ZHOU Na, YANG Jing

Department of Cardiology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China

Received:2013-07-06 Revised:2013-08-08 Published:2013-09-07

摘要/Abstract

摘要： 目的: 探讨血清高敏C反应蛋白(hs-CRP)、组织蛋白酶S(CatS)与急性冠脉综合征的相关关系。方法: 选择53例急性冠脉综合征患者(ACS组),对照组36例,检测两组血清CatS、hs-CRP水平并进行比较。同时检测ACS组治疗后血清hs-CRP、CatS水平的变化。结果: ACS组在性别、年龄、吸烟、糖尿病、脑梗死、高血压患病率方面与对照组相比,差异无统计学意义(P>0.05);ACS组治疗前血清CatS水平为(0.51±0.03) nmol/L,hs-CRP为(10.21±5.03) mg/L,分别高于对照组的(0.43±0.04) nmol/L 和(3.64±1.87) mg/L,差异具有统计学意义(P<0.05); ACS组治疗后血清CatS、hs-CRP水平分别为(0.45±0.06) nmol/L 和(6.05±3.25) mg/L,较治疗前的(0.51±0.03) nmol/L 和(10.21±5.03) mg/L 明显降低,差异有统计学意义(P<0.05)。结论: ACS患者血清CatS及hs-CRP的水平的变化提示 CatS及hs-CRP可能在ACS发生发展过程中具有重要作用,推测 CatS可能作为ACS的一种新的生物标志物。

关键词: 组织蛋白酶S, 急性冠脉综合征, 高敏C反应蛋白

Abstract: AIM: To investigate the serum high sensitive creactive protein(hs-CRP), cathepsin S (CatS) level changes and clinical significance in acute coronary syndrome patients. METHODS: All patients were divided into acute coronary syndrome (ACS group,n=53) and control group(n=36).The levels of serum hs-CRP and CatS in two groups were detected and compared before and after treatment.RESULTS: There were no significant difference of two groups in gender, age, smoking, diabetes, cerebral infarction, hypertension prevalence rate. The levels of serum CatS and hs-CRP in ACS group before treatment and control group were (0.51±0.03) nmol/L,(10.21±5.03) mg/L and (0.43±0.04) nmol/L,(3.64±1.87) mg/L,respectively;there were statistically significant differences(P<0.05).After treatment,the levels of serum CatS and hs-CRP in ACS group were (0.45±0.06) nmol/L and (6.05±3.25) mg/L, compared with before treatment (0.51±0.03) nmol/L and (10.21±5.03) mg/L, which were significantly decreased, there were statistically significant differences(P<0.05).CONCLUSION: Changes of hs-CRP, CatS level in ACS patients suggest that hs-CRP and CatS may play an important role in acute coronary syndrome, CatS may possibly act as a new biomarker of ACS.

Key words: Cathepsin S, Acute coronary syndrome, High sensitive creactive protein

中图分类号:

R541.4

周碧蓉, 陈越峰, 周娜, 杨景. 急性冠脉综合征患者血清高敏C反应蛋白和组织蛋白酶S水平变化与临床意义[J]. 中国临床药理学与治疗学, 2013, 18(9): 1036-1039.

ZHOU Bi-rong, CHEN Yue-feng, ZHOU Na, YANG Jing. Changes of hs-CRP, CatS level in acute coronary syndrome patients serum and clinical significance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1036-1039.

参考文献

[1] Benjamin S, David M, Elliott A, et al. Timing and Clinical Setting of Cardiovascular Death or Myocardial Infarction Following PCI for ACS- Observations from the Triton - Timi 38 Trial [J]. JACC, 2012, 59(13): E340.
[2] Chan CP, Rainer TH.Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome [J].Adv Clin Chem, 2013, 59: 23-63.
[3] de Nooijer R, Bot I, von der Thüsen JH, et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis [J]. Arterioscler Thromb Vasc Biol, 2009, 29(2): 188-194.
[4] Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J]. N Engl J Med, 2004, 350 (14): 1387-1397.
[5] Guangling C, Shen W, Wenqin C.Beneficial Effects of atorvastatin on high sensitivity c-reactive protein and renal function in patients with coronary artery disease undergone coronary angiography [J]. J Clin Cardi, 2011, 27(5): 355-357.
[6] Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J]. N Engl J Med, 2004, 350(15): 1495-1504.
[7] 贾亮亮,柯永胜.急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略 [J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.
[8] Plenge JK, Hernandez TL, Weil KM, et al. Sim vastatin lowers C -reactive protein within 14 days: an effect independent of low -density lipoprotein cholesterol reduction [J]. Circulation, 2002, 106(12): 1447-1452.
[9] 胡雪松,吴泽彬,许香广.阿托伐他汀短期干预对ACS患者APN和hs- CRP的影响 [J]. 广东医学, 2009, 30(7): 1158-1160.
[10] Samokhin AO,Lythgo PA,Gauthier JY,et al.Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice[J]. J Cardiovasc Pharmacol, 2010, 56(1): 98-105.
[11] Qin Y, Shi GP. Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases [J]. Pharmac Ther, 2011, 131(3): 338-350.

[1]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[2]	邓毅凡, 何胜虎, 王大新, 戴承晔, 徐笑挺, 张晶. 依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 1048-1052.
[3]	张倩, 付红, 陈瑾瑾, 朱余兵. IL-33/ST2在急性冠脉综合征中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1075-1080.
[4]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.
[5]	章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.
[6]	张银妆, 陈碧莲. 抗血小板膜P₂Y₁₂受体拮抗剂的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(7): 824-830.
[7]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.
[8]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J]. 中国临床药理学与治疗学, 2012, 17(9): 1074-1080.
[9]	廖祥明. 血脂康抗心衰药效的临床研究及其降低血浆脑钠肽的相关性[J]. 中国临床药理学与治疗学, 2010, 15(11): 1284-1287.
[10]	柯永胜. 新型抗凝药物直接Xa因子抑制剂利伐沙班[J]. 中国临床药理学与治疗学, 2009, 14(4): 361-367.
[11]	陈碧莲, 解勤之, 李清. 急性冠脉综合征患者氯吡格雷抵抗与近期疗效的临床观察[J]. 中国临床药理学与治疗学, 2009, 14(3): 328-332.
[12]	吴旭斌, 钱宗杰, 伍广伟, 林英忠, 胡昌兴. 罗格列酮对无糖尿病急性冠脉综合征患者外周血单核细胞合成TNF-α和组织因子的影响[J]. 中国临床药理学与治疗学, 2009, 14(2): 180-185.
[13]	吴旭斌, 汤圣兴, 伍广伟, 林英忠, 胡昌兴. 阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响[J]. 中国临床药理学与治疗学, 2009, 14(1): 98-102.
[14]	张品, 何胜虎, 陈述, 张惹, 严风姊, 燕建峰, 赵福全, 徐返华. 曲美他嗦对非ST段抬高急性冠脉综合征患者心肌缺血和心率变异的影响[J]. 中国临床药理学与治疗学, 2007, 12(12): 1432-1435.
[15]	刘彦, 陈绍良, 刘志忠. 急性冠脉综合症患者冠状动脉侧支的临床意义[J]. 中国临床药理学与治疗学, 2006, 11(6): 681-683.